Fluence Collaboration With Dutch Propagator WPK Creates Immediate Improvements in Plant Quality and Uniformity
14.9.2022 15:30:00 EEST | Business Wire | Press release
Fluence, a leading global provider of energy-efficient LED lighting solutions for commercial cannabis and food production, announced today its collaboration with Westlandse Plantenkwekerij (WPK), a large Dutch propagator specializing in young plant cultivation for greenhouse horticulture in Europe.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220914005286/en/
One of the larger propagators in the Netherlands, Westlandse Plantenkwekerij, implemented a hybrid lighting approach using Fluence’s VYPR fixtures, resulting in increased quality and control over environmental factors. (Photo: Business Wire)
Originally founded in the 1930s by Arie van der Arend, WPK is a multi-generational family business now run by van der Arend’s descendants, Erik and Eviek. As a propagator, WPK oversees the seed-to-plant process for vegetable and tray plants for growers throughout Europe. The company’s scientific approach to cultivation has led to decades of success, ultimately driving WPK to enlist Fluence’s help to install research-backed LED lighting at their ’s-Gravenzande facility, jointly owned with Plantenkwekerij P. van Geest, for the very first time.
WPK introduced Fluence’s VYPR Series top lights alongside existing legacy high-pressure sodium (HPS) fixtures to harness the unique control a hybrid lighting approach offers for optimizing environmental factors—including controlling ambient heat. The hybrid lighting model at WPK’s facilities has led to better management of seasonal growing conditions and notable energy savings.
“After installing Fluence’s LED lighting solutions, we learned that young plants thrive in LED-lit environments,” said Erik van der Arend, managing director of WPK. “This has allowed us the flexibility to grow a wide range of crops in the same environment and under the same lighting conditions, decreasing hassle and improving our energy costs. The transition to Fluence has helped improve plant quality and speed of development, ensuring our customers get a uniform product that is consistently excellent.”
In collaboration with Fluence’s horticultural lighting experts, WPK fine-tuned the LEDs’ spectra to optimize operational costs while maintaining superior quality for the grower’s tomato, cucumber, pepper and flower crops. Early results show that WPK is realizing an estimated electricity savings between 40 and 50% by using two-thirds Fluence LED fixtures and one-third HPS in the greenhouse. Additionally, WPK increased total light levels by 30% due to the overall efficiency of LED technology. The post-installation harvests produced more compact, generative and vigorous plants that were darker or richer in color.
“The interesting thing about Fluence’s lighting technology is the right degree of cooling—the luminaire doesn’t get very hot,” van der Arend added. “Moreover, the spectrum is widely applicable.”
“When you work with Fluence, you’re not just buying a standalone LED light. You’re tapping into a network of leading lighting and horticultural experts who can help you create the right conditions to optimize your cultivation environment,” said Timo Bongartz, general manager of Europe, Middle East and Africa at Fluence. “That’s why we love working with propagators like WPK who share our passion for developing innovative lighting and environmental control strategies.”
For more information about the collaboration, visit here.
About Fluence
Fluence Bioengineering, Inc. (Fluence) creates powerful and energy-efficient LED lighting solutions for commercial crop production and research applications. Fluence is a leading LED lighting supplier in the global cannabis market and is committed to enabling more efficient crop production with the world’s top vertical farms and greenhouse produce growers. Fluence global headquarters are in Austin, Texas, with its EMEA headquarters in Rotterdam, Netherlands. Fluence operates as a business unit within Signify’s Digital Solutions division. For more information about Fluence, visit www.fluence.science.
About WPK
Westlandse Plantenkwekerij (WPK) is a specialist in vegetable cultivation for professional greenhouse horticulture in Europe. WPK was established in the 1930s and currently has four cultivation facilities: two in 's-Gravenzande (South-Holland) and two in Made (North-Brabant). WPK makes the world a little greener with the cultivation of vegetable plants (such as tomato, pepper and cucumber), tray plants and potted flowering plants.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220914005286/en/
Contact information
Media Contact:
For EMEA,
Silvia Nagyova
silvia.nagyova@fluence-led.com
+49 (89) 6213-3939
For North America,
Emma Chase
pr@fluencebioengineering.com
512-917-4319
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
